Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BIO201

            Therapeutic Area: Ophthalmology Product Name: Macuneos

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: BPI

            Deal Size: $1.1 million Upfront Cash: Undisclosed

            Deal Type: Funding April 29, 2021

            Details:

            Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IC 800

            Therapeutic Area: Ophthalmology Product Name: IC 800

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: IACTA PHARMACEUTICALS

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 07, 2021

            Details:

            Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 (acute) and IC805 and other DENKI drugs from Pharmaleads’ portfolio.